\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ mild\\ bilateral\\ flank\\ pain\\.\ \(0\)\
\-\ labs\\:\\ elevated\\ serum\\ calcium\\.\ \(0\)\
\-\ to\\ follow\\.\ \(3\)\
\-\ 1\\.\\ lungs\\ with\\ reticulonodular\\ interstitial\\ pattern\\.\ \(0\)\
\-\ 2\\.\\ nephrolithiasis\\.\ \(0\)\
\-\ 3\\.\\ diffuse\\ lymphadenopathy\\.\ \(0\)\
\-\ sarcoidosis\\.\ \(14\)\
\-\ tuberculosis\\ \ \(30\)\
\-\ \\ lymphoma\\ \\-\\ almost\\ never\\ shows\\ the\\ striking\\ symmetry\\ \ \(0\)\
\-\ \\ carcinoma\\ \\(metastatic\\)\\ \ \(0\)\
\-\ \\ sarcoid\ \(138\)\
\-\ \\ fungal\\ disease\ \(3\)\
\-\ 34\\ year\\ old\\ female\\ presents\\ to\\ the\\ emergency\\ room\\ with\\ abdominal\\ pain\\.\ \(1\)\
\-\ the\\ patient\\ presented\\ with\\ abdominal\\ pain\\ secondary\\ to\\ bilateral\\ nephrolithiasis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.3742106913525488\ \(0\)\
\-\ symmetry\\:\\ 0\\.23479735827901388\ \(0\)\
\-\ reticulonodular\\:\\ 0\\.21821426814068287\ \(0\)\
\-\ striking\\:\\ 0\\.2116104777463381\ \(0\)\
\-\ abdominal\\:\\ 0\\.19500300118821468\ \(0\)\
\-\ bilateral\\:\\ 0\\.1916195385753174\ \(0\)\
\-\ pain\\:\\ 0\\.19137648334491203\ \(0\)\
\-\ never\\:\\ 0\\.18779222616281055\ \(0\)\
\-\ sarcoid\\:\\ 0\\.16718961093227022\ \(0\)\
\-\ interstitial\\:\\ 0\\.16161170204591205\ \(0\)\
\-\ calcium\\:\\ 0\\.16101641158872432\ \(0\)\
\-\ almost\\:\\ 0\\.1601442116105463\ \(0\)\
\-\ serum\\:\\ 0\\.15985880502351776\ \(0\)\
\-\ fungal\\:\\ 0\\.15957598133694725\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.1568801899580141\ \(0\)\
\-\ flank\\:\\ 0\\.156367853826878\ \(0\)\
\-\ 34\\:\\ 0\\.15536771074513955\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.1510105987454246\ \(0\)\
\-\ pe\\:\\ 0\\.147377270063009\ \(0\)\
\-\ room\\:\\ 0\\.1458888076075693\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.14412269908462993\ \(0\)\
\-\ to\\:\\ 0\\.13370269558546344\ \(0\)\
\-\ pattern\\:\\ 0\\.13309639461179612\ \(0\)\
\-\ emergency\\:\\ 0\\.13226296377898705\ \(0\)\
\-\ lungs\\:\\ 0\\.13156586861542777\ \(0\)\
\-\ labs\\:\\ 0\\.12350824380694132\ \(0\)\
\-\ elevated\\:\\ 0\\.12153016554421182\ \(0\)\
\-\ diffuse\\:\\ 0\\.11179839753718235\ \(0\)\
\-\ the\\:\\ 0\\.10671496825015721\ \(0\)\
\-\ carcinoma\\:\\ 0\\.10663405026174391\ \(0\)\
\-\ lymphoma\\:\\ 0\\.10617181301561422\ \(0\)\
\-\ secondary\\:\\ 0\\.1056661093587398\ \(0\)\
\-\ with\\:\\ 0\\.10472346013911465\ \(0\)\
\-\ shows\\:\\ 0\\.10463004307105098\ \(0\)\
\-\ presented\\:\\ 0\\.10395793535910992\ \(0\)\
\-\ mild\\:\\ 0\\.10105713641810092\ \(0\)\
\-\ metastatic\\:\\ 0\\.09777308843431762\ \(0\)\
\-\ follow\\:\\ 0\\.09610390608550248\ \(0\)\
\-\ female\\:\\ 0\\.08602429910148332\ \(0\)\
\-\ presents\\:\\ 0\\.08575787119566006\ \(0\)\
\-\ disease\\:\\ 0\\.07483211034687665\ \(0\)\
\-\ patient\\:\\ 0\\.05798282204511236\ \(0\)\
\-\ year\\:\\ 0\\.054939816204319376\ \(0\)\
\-\ old\\:\\ 0\\.05276124144548461\ \(0\)\
